← FDA DRUG APPROVALS

FDA NDA · NDA219910

EPIOXA CROSS-LINKING

riboflavin 5-phosphate ophthalmic

Sponsor: GLAUKOS

APPLICATION
NDA219910
TYPE
NDA
ORIGINAL APPROVAL
2025-10-17
LATEST ACTION
2025-10-17
ROUTE
OPHTHALMIC
DOSAGE FORM
SOLUTION/DROPS
MARKETING STATUS
Prescription

Products

EPIOXA HD/EPIOXA KIT · ReferencePrescription
RIBOFLAVIN 5'-PHOSPHATE SODIUM EQ 0.239% BASE/ML · SOLUTION/DROPS · OPHTHALMIC

Approval history

2025-10-17Type 5 - New Formulation or New Manufacturer · Original · standard — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →